Trump FDA chief is leaving after angering pharma CEOs, vaping lobbyists and anti-abortion groups
Briefly

Trump FDA chief is leaving after angering pharma CEOs, vaping lobbyists and anti-abortion groups
"The head of the Food and Drug Administration, Dr. Marty Makary, is resigning after a rocky tenure that drew months of complaints from health industry executives, anti-abortion activists, vaping lobbyists and other allies of President Donald Trump."
"Makary faced a unique challenge in balancing calls by Trump and other Republicans to cut red tape at the FDA, while also tending to Kennedy's interest in scrutinizing of the safety vaccines, drugs and food additives."
"But he struggled to manage the FDA's bureaucracy and failed to win the confidence of its staff after mass layoffs, leadership changes and a series of controversies in which the agency's scientific principles appeared to be overridden by political interests, including those of Health Secretary Robert F. Kennedy Jr."
"Virtually all of FDA's senior career officials resigned, retired or were forced out in the first year of the second-term Trump administration, leading to a steady stream of leaks and negative stories in the media cataloging"
Marty Makary is resigning as commissioner of the Food and Drug Administration after just over a year in the role. His tenure drew complaints from health industry executives, anti-abortion activists, vaping lobbyists, and other allies of President Donald Trump. Kyle Diamantas, the agency’s chief for foods, will become acting commissioner. Makary, a surgeon and health researcher, gained prominence among Republicans by criticizing COVID-19 health measures and appearing frequently on Fox News. He struggled to manage FDA bureaucracy and failed to win staff confidence after mass layoffs, leadership changes, and controversies suggesting scientific principles were overridden by political interests, including those tied to Health Secretary Robert F. Kennedy Jr. The FDA commissioner must balance science and politics while responding to calls to cut regulatory red tape and to vaccine and drug safety scrutiny.
Read at Boston.com
Unable to calculate read time
[
|
]